Antiplatelet Agents

Antiplatelet agents prevent arterial clot formation by blocking platelet activation and aggregation — the initial plug that triggers thrombus growth in high-flow vessels like coronary and cerebral arteries. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), blocking thromboxane A2 production for the platelet's entire 7–10 day lifespan. Low-dose aspirin (81 mg daily) is standard for long-term cardiovascular prevention. P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) block ADP-mediated platelet activation through a different pathway. Dual antiplatelet therapy (DAPT) — aspirin plus a P2Y12 inhibitor — is the standard after acute coronary syndrome and stent placement, typically continued for at least 12 months. GP IIb/IIIa inhibitors (eptifibatide, abciximab) are IV agents used during percutaneous coronary intervention that block the final common pathway of platelet cross-linking. The critical nursing concern across all antiplatelets is bleeding risk. You monitor for overt bleeding (gums, stool, urine, bruising) and covert signs (unexplained tachycardia, hypotension, declining hemoglobin). Antiplatelets must be held before elective surgery to restore platelet function — typically 7–10 days for aspirin, 5–7 days for clopidogrel, and 5 days for ticagrelor. Teach the client never to stop DAPT without provider approval — premature discontinuation after stenting carries a high risk of stent thrombosis, which can be fatal.